جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

478 مُخرَج نتائج البحث عن «Cancer»

مقالوصول مغلق202513استشهاد· Semantic Scholar

Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities

Archiv der Pharmazie · مجلد 358 (7) · e70042-e70042

ABSTRACT A series of thiadiazole‐based derivatives were synthesized and evaluated for their potential as VEGFR‐2 inhibitors and anticancer agents. Among them, compound 7b demonstrated significant cytotoxic activity against MCF‐7 breast cancer cells, with an IC 50 value of 6.13 µM, surpassing that of the reference drug sorafenib (IC 50 : 7.26 µM). Compound 7b also exhibited potent VEGFR‐2 inhibition with an IC 50 of 40.65 nM, outperforming sorafenib (IC 50 : 53.32 nM). Further investigation into the mechanism of action revealed that compound 7b induced significant changes in the cell‐cycle distribution of MCF‐7 cells, causing G1 arrest and delaying progression through the G2/M phase. Apoptosis analysis demonstrated that compound 7b primarily induced late apoptosis (55.90%) and necrosis (21.81%), with only 22.26% of cells remaining viable. Treatment with 7b increased the expression of the proapoptotic gene BAX (4.19 ± 0.34‐fold) and suppressed the expression of the antiapoptotic gene Bcl‐2 (0.38 ± 0.02‐fold), resulting in a dramatic increase in the BAX/Bcl‐2 ratio (11.03 ± 1.66‐fold). Additionally, caspase‐8 and caspase‐9 levels were elevated by 2.99 ± 0.22‐fold and 4.13 ± 0.11‐fold, respectively, confirming activation of both intrinsic and extrinsic apoptotic pathways. In conclusion, compound 7b is a potent VEGFR‐2 inhibitor with promising anticancer activity, demonstrating cytotoxicity, inhibition of cell migration, and induction of apoptosis in MCF‐7 cells. These results suggest that compound 7b has the potential to be developed as a therapeutic agent for breast cancer treatment, warranting further in vivo and mechanistic studies.

thiadiazole derivativesVEGFR-2 inhibitorsanticancer agentsbreast cancer
مقالوصول مفتوح202513استشهاد· Semantic Scholar

Comparative mechanistic study of green-synthesized silver-zinc oxide (Ag-ZnO) and iron–Zinc oxide (Fe-ZnO) bimetallic nanoparticles in antiglycation, antidiabetic, antioxidant, and anticancer activities

Journal of Taibah University for Science · مجلد 19 (1)

Bimetallic nanoparticles (BNPs) have gained immense attention for their diverse biological applications. This study aimed to biosynthesize and characterize Ag-ZnONPs and Fe-ZnONPs and compare their potential as therapeutic agents. The BNPs were synthesized using Mentha asiatica plant extract and characterized using various techniques such as UV-visible spectroscopy, TEM, EDX spectroscopy, ATR-FTIR spectroscopy, PXRD, DLS, and zeta potential analyses. TEM, EDX, and XRD revealed the structural and morphological properties of crystalline Ag-ZnONPs and Fe-ZnONPs. FTIR analysis investigated the plant phytochemicals responsible for the stabilization and capping of BNPs. Ag-ZnONPs showed higher biocompatibility than Fe-ZnONPs. Fe-ZnONPs exhibited-significantly higher anticancer potential than Ag-ZnONPs as evident by Reactive Oxygen Species/ Nitric Oxide Synthase production, along with cell viability analysis, loss of mitochondrial-membrane potential, enhanced caspase-3 gene-expression, and intensified activity of Caspase-3/7. Collectively, our findings underscore the promising therapeutic-potential of BNPs in cancer treatment and diabetes, setting them as strong candidates for future biomedical applications.

bimetallic nanoparticlesgreen synthesisphytochemicalsantioxidant activity
مقالوصول مفتوح202513استشهاد· Semantic Scholar

Targeting VEGFR-2 in breast cancer: synthesis and in silico and in vitro characterization of quinoxaline-based inhibitors

RSC Advances · مجلد 15 (17) · 12896-12916

ADMET analysis predicted a favorable safety profile over sorafenib, particularly with respect to carcinogenic and chronic toxicity risks. These findings indicate that quinoxaline derivative 11d holds potential as a selective and effective VEGFR-2 inhibitor with promising antitumor and anti-metastatic properties, warranting further investigation.

VEGFR-2 inhibitorsbreast cancerquinoxaline derivativessmall molecule inhibitors
مقالوصول مفتوح202511استشهاد· Semantic Scholar

Aotaphenazine, a rare hydrophenazine, targets topoisomerase II with anticancer efficacy: In silico to in vitro evidence

PLoS ONE · مجلد 20 (12) · e0338135-e0338135

BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.

topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation
مقالوصول مفتوح202511استشهاد· Semantic Scholar

AI-Driven Predictive Modeling for Lung Cancer Detection and Management Using Synthetic Data Augmentation and Random Forest Classifier

International Journal of Computational Intelligence Systems · مجلد 18 (1)

Artificial intelligence (AI) transforms multiple businesses, including medical research, where AI-driven developments bring significant advantages. The application of machine learning algorithms enables medical researchers to examine large amounts of data accurately, which leads to the development of precise and effective treatment approaches. Lung cancer leads the list of critical healthcare issues because it remains the world’s most lethal form of cancer thus demanding innovative diagnostic tools for faster and accurate identification. The proposed study introduces an innovative method called CTGAN-RF which uses conditional tabular generative adversarial networks (CTGAN) and random forest (RF) classifier to detect lung cancer through synthetic data generation. The proposed model demonstrated superior performance by achieving a 0.9893 score of accuracy and 0.99 value for precision, F1 score, and recall. Extensive experimental evaluation for this method included testing nine classification algorithms. The implementation of different classifiers employed data balancing methods including SMOTE and borderline-SMOTE along with SMOTE ENN and unbalanced data configurations. Comparative analysis showed that CTGAN-RF consistently performed significantly better than traditional classifiers in dealing with class imbalance and improving prediction accuracy. After testing with fivefold cross-validation, the reliability of the model was further validated. In comparison to cutting-edge approaches for lung cancer diagnosis, the proposed methodology outperformed in terms of classification metrics. This in-depth evaluation of synthetic data augmentation with machine learning in lung cancer detection has helped in the development of personalized treatment strategies in the fight against such a life-threatening disease.

lung cancer detectionsynthetic data augmentationCTGANrandom forest
مقالوصول مفتوح202510استشهاد· Semantic Scholar

Sustainable green synthesis of zinc oxide nanoparticles utilizing Zingiber officinale peel aqueous extract, characterization, and determination of its anticancer and antimicrobial potential

PLoS ONE · مجلد 20 (11) · e0334685-e0334685

This study demonstrates the green synthesis, characterization, and biomedical applications of zinc oxide nanoparticles (ZnONPs) using Zingiber officinale (Z. officinale) (ginger) peel extract. Green synthesis offers advantages over conventional methods, including environmental friendliness, cost-effectiveness, and enhanced biocompatibility. Ultraviolet-Visible (UV-Vis) spectroscopy confirmed ZnONPs formation with a peak at 364 nm. Fourier-Transform Infrared (FTIR) spectroscopy analysis revealed characteristic peaks indicating functional groups involved in nanoparticle formation. Scanning Electron Microscope (SEM) analysis showed spherical/agglomerated nanoparticles, and Energy-Dispersive X-ray Spectroscopy (EDS) confirmed 77.7% zinc oxide by mass%. The X-ray Diffraction (XRD) indicated an average particle size of 24.67 nm with distinct crystal orientations. Phytochemical analysis detected alkaloids, saponins, and steroids in the extract. Optimal synthesis occurred at 50-60°C and pH 10, yielding stable ZnONPs. The ZnONPs exhibited significant antibacterial activity against Staphylococcus aureus (S. aureus), Bacillus subtilis (B. subtilis), Bacillus cereus (B. cereus), Escherichia coli (E.coli), Zymomonas mobilis (Z. mobilis), and Pseudomonas aeruginosa (P. aeruginosa), as well as antifungal activity against Candida albicans (C. albicans). The in vitro cytotoxicity study on M.D. Anderson - Metastatic Breast - 231 (MDA-MB-231) breast cancer cells showed a dose-dependent reduction in cell viability [Half-maximal Inhibitory Concentration (IC50) = 82.13 µg/mL] with notable morphological changes at higher concentrations. The ZnONPs synthesized from ginger peel extract are innovative, environmentally friendly, and economical. Our findings show that biologically generated ZnONPs are effective antibacterial and antifungal agents against several pathogens. This research uniquely demonstrates the potential of ginger peel, a commonly discarded agro-waste, as a sustainable source for ZnONPs synthesis, highlighting its biotechnological and medicinal applications. The novelty of this study lies in the green synthesis approach using ginger peel and the comprehensive evaluation of its antimicrobial and anticancer properties. Further in-depth studies and optimization are needed to validate their therapeutic efficacy and safety.

zinc oxide nanoparticlesgreen synthesisgingerantibacterial activity
مقالوصول مغلق202510استشهاد· Semantic Scholar

Integrated Computational and Experimental Discovery of a Promising Xanthine Derivative with Anticancer Potential Targeting EGFR

Current Cancer Drug Targets · مجلد 25

INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.

xanthine derivativestheobromineacetanilideEGFR inhibitors
مقالوصول مفتوح202510استشهاد· Semantic Scholar

A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy

PLoS ONE · مجلد 20 (9) · e0328305-e0328305

A novel sulfamoylphenyl-dihydro-thiadiazole derivative (compound 14) has been designed and synthesized as a dual inhibitor targeting EGFR and human carbonic anhydrases (hCA_IX and hCA_XII). Computational studies, including density functional theory (DFT), molecular docking, and molecular dynamics simulations, confirmed its stability, favorable binding interactions, and reactivity profiles. Compound 14 showed potent inhibition of EGFR (IC₅₀ = 10.12 ± 0.29 nM), hCA_IX and hCA_XII (IC₅₀ = 79 ± 1.2 nM and 58 ± 0.9 nM, respectively). Cytotoxicity assays demonstrated selective activity against cancer cells, with IC₅₀ values of 16.13 µM in MDA-MB-231 and 22.57 µM in MCF-7 cells, compared to 148.32 µM in non-cancerous Vero cells. Compared to acetazolamide, compound 14 exhibited improved selectivity for cancer cells. Apoptosis studies revealed significant cell death in MDA-MB-231 cells, with early and late apoptosis rates of 22.50% and 58.27%, respectively, alongside a marked G1-phase cell cycle arrest (49.10% in treated cells vs. 44.98% in controls). In silico toxicological evaluations indicated a favorable safety profile, with low irritancy and acceptable rat oral LD₅₀ (15.81 mg/kg) and carcinogenic potency (TD₅₀ = 36.95). Compound 14's potent dual inhibition and selective cytotoxicity make it a promising candidate for further optimization and in vivo studies.

EGFR inhibitorscarbonic anhydrase IXcarbonic anhydrase XIIcancer therapy
مقالمفتوح (مستودع)202510استشهاد· Semantic Scholar

Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis induction

Future Medicinal Chemistry · مجلد 17 (17) · 2145-2162

BACKGROUND: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles. METHODS: A series of 2,3-dihydro-1,3,4-thiadiazole derivatives was rationally designed, synthesized, and structurally characterized. In vitro cytotoxicity was assessed against MCF-7, HepG-2, HCT-116, and normal WI-38 cells. Mechanistic assays included flow cytometry for cell cycle and apoptosis, and ELISA for caspase-3, Bcl-2, and Bax expression. Molecular docking, 200-ns molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and in silico toxicity profiling supported experimental findings. RESULTS: Compound 11a exhibited the most potent and selective activity (IC₅₀: 9.49 µM for MCF-7, 12.89 µM for HepG-2; SI > 3). It induced >70% apoptosis and dual-phase (S and G2/M) cell cycle arrest. VEGFR-2 inhibition (IC₅₀ = 0.055 µM) was comparable to sorafenib. Computational studies confirmed stable binding at VEGFR-2 active sites. CONCLUSION: Compound 11a is a promising thiadiazole-based candidate with notable in vitro potency, selectivity, and mechanistic activity, supporting its potential for further pharmacokinetics/toxicity evaluation and structural refinement as a VEGFR-2-targeted agent.

VEGFR-2 inhibitorsthiadiazole derivativesanticancer drug discoveryapoptosis induction
مقالمفتوح (مستودع)202510استشهاد· Semantic Scholar

Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors

Future Medicinal Chemistry · مجلد 17 (9) · 1023-1038

Background Thiadiazole-sulfonamide derivatives were synthesized as dual inhibitors of epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) to develop selective anticancer agents.Methods Cytotoxicity was evaluated against MDA-MB-231 and MCF-7 breast cancer cells, with selectivity tested on Vero cells. Enzymatic inhibition studies were conducted against EGFR and CA-IX, using erlotinib and acetazolamide as reference drugs. Apoptosis was assessed through gene expression analysis of BAX/Bcl-2, caspase-8, and caspase-9, alongside flow cytometry for apoptosis and cell cycle analysis. Molecular docking and 200 ns molecular dynamics (MD) simulations evaluated binding interactions. Density Functional Theory (DFT) calculations and in silico ADMET predictions assessed stability, electronic properties, and safety.Results Compound 14 exhibited potent cytotoxicity (IC₅₀ = 5.78 μM, MDA-MB-231; 8.05 μM, MCF-7) and high selectivity (IC₅₀ = 313.08 μM, Vero). It inhibited EGFR (IC₅₀ = 5.92 nM) and CA-IX (IC₅₀ = 63 nM), surpassing reference drugs. Apoptosis induction was confirmed by a 13.97-fold increase in BAX/Bcl-2, caspase upregulation, and G1-phase arrest. Computational analyses confirmed stable binding and favorable safety.Conclusions Compound 14 represents a promising dual EGFR/CA-IX inhibitor with selective anticancer activity. Further in vivo studies are warranted.

EGFR inhibitorscarbonic anhydrase IX inhibitorsanticancer agentsbreast cancer
مقالمفتوح (مستودع)20259استشهاد· Semantic Scholar

Development of novel furan-based VEGFR-2 inhibitors and apoptotic inducers for colorectal cancer

Future Medicinal Chemistry · مجلد 17 (24) · 2959-2973

Aims This study aimed to synthesize and evaluate novel furan derivatives as potential anticancer agents targeting colon cancer through VEGFR-2 inhibition and apoptosis induction.Materials and methods The cytotoxic activity of the synthesized compounds was assessed against human fibroblast (HSF) and colon cancer cell lines (HCT-116, Caco-2, and HT-29) using the MTT assay. VEGFR-2 inhibitory activity was determined in vitro, and immunocytochemistry was employed to evaluate VEGFR-2 expression. Apoptosis, cell cycle arrest, and migration inhibition were analyzed in Caco-2 cells. Molecular docking, molecular dynamics (MD) simulations, Density Functional Theory (DFT), and ADMET analyses were conducted to assess binding affinity, stability, and safety profiles.Results Compound 6 exhibited potent cytotoxicity against HT-29 (IC50 = 22.39 μM) and strong VEGFR-2 inhibition (IC50 = 0.28 ± 0.42 μM), comparable to sorafenib. It suppressed VEGFR-2 expression, induced G2/M cell cycle arrest, and promoted early and late apoptosis in 97% of treated Caco-2 cells. Upregulation of Bax and caspase-3, along with downregulation of Bcl-2, confirmed intrinsic apoptotic activation. Computational analyses supported compound 6’s stability and drug-likeness.Conclusions Compound 6 is a promising lead furan derivative with potent, selective anticancer activity against colon cancer via VEGFR-2 inhibition and apoptosis induction. Further, in vivo evaluation is warranted.

furan derivativesVEGFR-2 inhibitorscolorectal cancerapoptosis induction
مراجعةمفتوح (مستودع)20259استشهاد· Semantic Scholar

Anticancer Potential of Wogonin: A Comprehensive Treatise

Food Science & Nutrition · مجلد 13 (11) · e71128-e71128

Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.

wogoninanticancer activityflavonoidsapoptosis